Get the Stockscreener App
1.66
1.19%
-0.02
After Hours:
1.68
0.02
+1.20%
Pacific Biosciences Of California Inc stock is traded at $1.66, with a volume of 3.89M.
It is down -1.19% in the last 24 hours and up +14.48% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
See More
Previous Close:
$1.68
Open:
$1.67
24h Volume:
3.89M
Relative Volume:
0.60
Market Cap:
$515.60M
Revenue:
$160.03M
Net Income/Loss:
$-128.58M
P/E Ratio:
-3.8894
EPS:
-0.4268
Net Cash Flow:
$-121.21M
1W Performance:
-4.05%
1M Performance:
+14.48%
6M Performance:
-20.19%
1Y Performance:
+3.75%
1-Day Range:
$1.61
$1.72
1-Week Range:
$1.605
$1.835
52-Week Range:
$1.09
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.66 | 521.81M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 2500 Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 2000 Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000E Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000 Growth Benchmark - marketscreener.com
PacBio (PACB) Stock Faces Mixed Analyst Target Changes After Valuation Revisions - Yahoo Finance
Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Pacific Biosciences of California, Inc. Actuals & Estimates (NASDAQ:PACB) - TradingView
PACIFIC BIOSCIENCES OF CALIFORNIA ROE % Adjusted to Book Val - GuruFocus
Enterprise value to revenue forward of Pacific Biosciences of California, Inc. – FWB:P09 - TradingView
Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – FWB:P09 - TradingView
PACB Forecast — Price Target — Prediction for 2027 - TradingView
PACB Stock Gains Focus As New Sequencing Tech Slashes Genome Costs - StocksToTrade
Price to book forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Pacific Biosciences of California launches kit to streamline high-throughput sequencing operations - Traders Union
Pacific Biosciences of California Inc (PACB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Price to sales forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
PACB & Blank Bio partner to advance RNA foundation models in oncology - MSN
Pacific Biosciences of California Inc (PACB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pacific Biosciences of California Inc (PACB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pacific Biosciences of California Inc (PACB) Institutional Confidence - TradingKey
Pacific Biosciences of California Inc - TradingKey
Pacific Biosciences of California Inc (PACB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pacific Biosciences of California Inc (PACB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pacific Biosciences of California Inc (PACB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Is Pacific Biosciences of California, Inc. (PACB) One of the Best Genomics Stocks to Buy According to Wall Street? - Insider Monkey
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
PacBio Announces a Private Convertible Exchange Transaction of $ - GuruFocus
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences of California Company Profile & Introduction - Moomoo
How The Pacific Biosciences (PACB) Investment Narrative Is Evolving Without New Analyst Targets - Yahoo Finance
Pacific Biosciences of California, Inc. 8-K Filing: 2020 Equity Incentive Plan Amendment, Stockholder Voting Results & Company Information (June 2026) – Minichart - Minichart
Pacific Biosciences (PACB) director receives 223,492 stock options at $1.58 strike - Stock Titan
Christopher Gibson (NASDAQ: PACB) receives 74,497 stock options grant - Stock Titan
PACIFIC BIOSCIENCES (PACB) director granted 223,492 stock options at $1.58 - Stock Titan
Director at Pacific Biosciences (PACB) receives 223,492 stock options grant - Stock Titan
PACB (PACB) director granted 223,492 stock options at $1.58 exercise price - Stock Titan
Pacific Biosciences reserves 16,000,000 additional shares under 2020 Equity Incentive Plan - TradingView
Director William W. Ericson granted 223,492 PACB options at $1.58 exercise price - Stock Titan
Director John Milligan receives 223,492 options at PacBio (PACB) - Stock Titan
PacBio (PACB) director Kathy Ordonez receives 223,492 stock options at $1.58 - Stock Titan
Pacific Biosciences (PACB) shareholders approve 16M-share equity plan increase and 2026 auditor - Stock Titan
Pacific Biosciences (PACB) AGM 2024 Summary - Quartr
Here's Why You Should Add PacBio Stock to Your Portfolio Now - Zacks Investment Research
Pacific Biosciences announces accounting officer transition and litigation settlement - Investing.com
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026 - TradingView
Q1 Earnings Highs And Lows: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks - The Globe and Mail
Insiders At Pacific Biosciences of California Sold US$1.3m In Stock, Alluding To Potential Weakness - Moomoo
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology - TradingView
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.62%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):